The HPRT1 Knockout SK-HEP-1 Polyclonal Cells represent a robust genetically engineered cellular tool comprising a polyclonal population of SK-HEP-1 cells in which the HPRT1 gene has been disrupted through CRISPR/Cas9-mediated gene editing. This product provides a loss-of-function model for studying purine metabolism and related physiological processes without relying on a monoclonal isolate, thereby capturing heterogeneous genetic modification events across the population. The knockout approach targets the hypoxanthine phosphoribosyltransferase 1 (HPRT1) locus, abrogating its enzymatic activity and enabling dissection of purine salvage pathway contributions in a relevant human hepatic carcinoma background.
The parental SK-HEP-1 cell line originates from the ascites of a patient diagnosed with liver adenocarcinoma and is notable for its dual hepatocellular carcinoma and endothelial-like characteristics. This unique phenotype supports its widespread use in research on tumor metastasis, angiogenesis, and drug metabolism. Its adherent growth and genetic stability make it a reproducible platform for gene perturbation studies. When engineered to lack HPRT1, these cells serve as a syngeneic system to interrogate how purine salvage intersects with hepatic cancer cell behavior without the confounding variables introduced by cross-species differences.
HPRT1 encodes a transferase that catalyzes the conversion of hypoxanthine to inosine monophosphate (IMP) and guanine to guanosine monophosphate (GMP) using phosphoribosyl pyrophosphate (PRPP) as a co-substrate. This reaction is a key component of the purine salvage pathway, recycling preformed nucleobases into nucleotide pools. The enzyme??s transcription is regulated by the Sp1 transcription factor through housekeeping promoter elements. In the knockout model, disrupted HPRT1 leads to accumulation of its substrates hypoxanthine and guanine, which are subsequently oxidized by xanthine oxidase to uric acid, while depleting IMP and GMP levels. Consequently, cells become reliant on de novo purine synthesis and exhibit altered sensitivity to purine analogs such as 6-thioguanine, a phenotype frequently exploited in selection experiments.
Within the SK-HEP-1 background, HPRT1 loss is particularly significant due to the cell line??s relevance to hepatocellular carcinoma, a context where nucleotide metabolism is often reprogrammed to support rapid proliferation and chemoresistance. The endothelial features of these cells further allow the investigation of how purine imbalances influence processes like angiogenesis and metastatic dissemination. By enabling direct comparison between wild-type and knockout populations, researchers can attribute observed phenotypic changes specifically to HPRT1 deficiency, thereby clarifying its role in cancer cell adaptation and metabolic plasticity.
These polyclonal knockout cells are designed for diverse applications, including functional analysis of purine metabolism through enzyme activity assays and HPLC-based nucleotide quantification, modeling Lesch-Nyhan syndrome pathophysiology, and evaluating drug resistance mechanisms via cell viability assays with purine antimetabolites. They also support gene expression studies using RT-qPCR and Western blotting to validate target disruption and downstream effects on nucleotide pools. For detailed protocols and additional characterization data, please contact Ascent Research.
